Table 2 MI, PI and NDI in human peripheral blood lymphocytes treated with PMX + CFX for 24- and 48-h treatment periods

Control

-

-

5.11 ± 0.27

2.47 ± 0.03

1.54 ± 0.05

DMSO

24

9 μL

4.39 ± 0.13

2.31 ± 0.04

1.48 ± 0.03

MMC

24

0.25

1.99 ± 0.20

1.74 ± 0.09

1.31 ± 0.03

PMX + CFX

24

12.5 + 450

1.58 ± 0.25 a₃b₃

1.91 ± 0.04 a₃b₂

1.24 ± 0.03 a₃b₃c₁

25 + 800

1.70 ± 0.07 a₃b₃

1.85 ± 0.09 a₃b₃

1.17 ± 0.05 a₃b₃c₂

37.5 + 1150

1.67 ± 0.34 a₃b₃

2.01 ± 0.09 a₃b₁

1.17 ± 0.01 a₃b₃c₂

50 + 1500

1.25 ± 0.20 a₃b₃c₁

1.99 ± 0.14 a₃b₂

1.17 ± 0.01 a₃b₃c₃

DMSO

48

9 μL

2.48 ± 0.15

2.33 ± 0.04

1.38 ± 0.04

MMC

48

0.25

1.17 ± 0.19

1.39 ± 0.09

1.22 ± 0.03

PMX + CFX

48

12.5 + 450

0.70 ± 0.18 a₃b₃c₂

1.48 ± 0.07 a₃b₃

1.09 ± 0.03 a₃b₃c₂

25 + 800

0.84 ± 0.17 a₃b₃c₁

1.38 ± 0.05 a₃b₃

1.09 ± 0.02 a₃b₃c₂

37.5 + 1150

0.54 ± 0.19 a₃b₃c₂

1.22 ± 0.05 a₃b₃c₁

1.04 ± 0.01 a₃b₃c₃

50 + 1500

0.22 ± 0.14 a₃b₃c₃

1.26 ± 0.05 a₃b₃c₁

1.05 ± 0.01 a₃b₃c₃